TN2018000280A1 - Halo-substituted piperidines as orexin receptor modulators. - Google Patents
Halo-substituted piperidines as orexin receptor modulators.Info
- Publication number
- TN2018000280A1 TN2018000280A1 TNP/2018/000280A TN2018000280A TN2018000280A1 TN 2018000280 A1 TN2018000280 A1 TN 2018000280A1 TN 2018000280 A TN2018000280 A TN 2018000280A TN 2018000280 A1 TN2018000280 A1 TN 2018000280A1
- Authority
- TN
- Tunisia
- Prior art keywords
- halo
- disorder
- receptor modulators
- orexin receptor
- substituted piperidines
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 title 1
- 102000008834 Orexin receptor Human genes 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000012672 seasonal affective disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294940P | 2016-02-12 | 2016-02-12 | |
| US201662336102P | 2016-05-13 | 2016-05-13 | |
| PCT/US2017/017408 WO2017139603A1 (en) | 2016-02-12 | 2017-02-10 | Halo-substituted piperidines as orexin receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2018000280A1 true TN2018000280A1 (en) | 2020-01-16 |
Family
ID=59563558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2018/000280A TN2018000280A1 (en) | 2016-02-12 | 2017-02-10 | Halo-substituted piperidines as orexin receptor modulators. |
Country Status (34)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE059280T2 (hu) * | 2016-02-12 | 2022-11-28 | Astrazeneca Ab | Halogén-szubsztituált piperidinek mint orexin receptor modulátorok |
| CA3074059A1 (en) | 2017-09-01 | 2019-03-07 | Chronos Therapeutics Limited | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| EP3668864B1 (en) * | 2017-09-28 | 2021-07-21 | Boehringer Ingelheim International GmbH | N-(2,2-difluoroethyl)-n-[(pyrimidinylamino)propanyl]arylcarboxamides |
| US20210169883A1 (en) * | 2018-07-27 | 2021-06-10 | Icahn School Of Medicine At Mount Sinai | Method of treating aggression with orexin receptor antagonists |
| EP4053123A4 (en) | 2019-11-01 | 2023-10-11 | Unimatec Co., Ltd. | FLUORINATED PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF |
| GB202311280D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| GB202311281D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5049578A (en) | 1990-03-09 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| DK1348427T3 (da) | 1997-07-29 | 2008-06-30 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| ES2196806T3 (es) | 1998-05-08 | 2003-12-16 | Smithkline Beecham Plc | Derivados de fenilurea y de feniltiourea. |
| WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| AU2804400A (en) | 1999-02-12 | 2000-08-29 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| US6596730B1 (en) | 1999-02-12 | 2003-07-22 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives |
| EP1183235A2 (en) | 1999-05-24 | 2002-03-06 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| JPWO2001085693A1 (ja) | 2000-05-11 | 2004-01-08 | 萬有製薬株式会社 | Ｎ−アシルテトラヒドロイソキノリン誘導体 |
| WO2001096302A1 (en) | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
| ATE286897T1 (de) | 2000-11-28 | 2005-01-15 | Smithkline Beecham Plc | Morpholinderivate als antagonisten an orexinrezeptoren |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| CA2446396A1 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| NZ538029A (en) | 2002-07-09 | 2006-08-31 | Actelion Pharmaceuticals Ltd | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives |
| JP2006504695A (ja) | 2002-09-18 | 2006-02-09 | グラクソ グループ リミテッド | オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン |
| WO2004033418A2 (en) | 2002-10-11 | 2004-04-22 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| AU2003299648A1 (en) | 2002-12-12 | 2004-06-30 | Janssen Pharmaceutica, N.V. | Substituted 4-phenyl-(1,3)-dioxanes |
| DE602004021786D1 (de) | 2003-03-26 | 2009-08-13 | Actelion Pharmaceuticals Ltd | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten |
| US7538109B2 (en) | 2003-04-28 | 2009-05-26 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-one derivatives as orexin receptor antagonists |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| ES2593113T3 (es) | 2003-08-07 | 2016-12-05 | Allergan, Inc. | Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| HUP0304101A3 (en) | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| BRPI0508263B8 (pt) | 2004-03-01 | 2021-05-25 | Idorsia Pharmaceuticals Ltd | derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina |
| WO2006067224A2 (en) | 2004-12-23 | 2006-06-29 | Biovitrum Ab (Publ) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists |
| WO2006110626A1 (en) | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
| US7968289B2 (en) | 2005-05-03 | 2011-06-28 | Ensemble Therapeutics Corporation | Turn over probes and use thereof for nucleic acid detection |
| WO2006127550A1 (en) | 2005-05-23 | 2006-11-30 | Merck & Co., Inc. | Proline bis-amide orexin receptor antagonists |
| AU2006278575A1 (en) | 2005-08-04 | 2007-02-15 | Merck & Co., Inc. | Aminoethane sulfonamide orexin receptor antagonists |
| EP1922071A2 (en) | 2005-08-26 | 2008-05-21 | Merck & Co., Inc. | Diazaspirodecane orexin receptor antagonists |
| EP1954276A2 (en) | 2005-11-22 | 2008-08-13 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| CN101009515A (zh) | 2006-01-24 | 2007-08-01 | 华为技术有限公司 | 通信终端设备管理方法及通信终端 |
| TW200800020A (en) | 2006-01-26 | 2008-01-01 | Basf Ag | Methods to use 3-pyridyl derivatives as pesticides |
| FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
| JP2009533419A (ja) | 2006-04-11 | 2009-09-17 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルホンアミド化合物 |
| JP2009535324A (ja) | 2006-04-26 | 2009-10-01 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピラゾロ−テトラヒドロピリジン誘導体 |
| WO2007143813A1 (en) | 2006-06-16 | 2007-12-21 | Husky Injection Molding Systems Ltd. | Preventative maintenance update system |
| AU2007272795A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| SI2049529T1 (sl) | 2006-07-14 | 2010-11-30 | Merck Sharp & Dohme | Substituiran diazepan oreksin receptor antagonist |
| JP2009543785A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 架橋ジアゼパンオレキシン受容体アンタゴニスト |
| JP2010500401A (ja) | 2006-08-15 | 2010-01-07 | アクテリオン ファーマシューティカルズ リミテッド | アゼチジン化合物 |
| WO2008026149A1 (en) | 2006-08-28 | 2008-03-06 | Actelion Pharmaceuticals Ltd | 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists |
| WO2008038251A2 (en) | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| ATE496043T1 (de) | 2006-12-01 | 2011-02-15 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
| ES2380391T3 (es) | 2006-12-22 | 2012-05-11 | Actelion Pharmaceuticals Ltd. | Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina |
| CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| JP2010520206A (ja) | 2007-03-02 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピリジンカルボキサミドオレキシン受容体アンタゴニスト |
| WO2008107335A1 (en) | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
| WO2008110488A1 (en) | 2007-03-15 | 2008-09-18 | F. Hoffmann-La Roche Ag | Malonamides as orexin antagonists |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| AU2008235528B2 (en) | 2007-04-04 | 2012-11-08 | F. Hoffmann-La Roche Ag | Heterocycles as orexin antagonists |
| WO2008139416A1 (en) | 2007-05-14 | 2008-11-20 | Actelion Pharmaceuticals Ltd | 2-cyclopropyl-thiazole derivatives |
| JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| ES2379744T3 (es) | 2007-05-23 | 2012-05-03 | Merck Sharp & Dohme Corp. | Antagonistas de piridil-piperidina de los receptores de orexinas |
| BRPI0813218A2 (pt) | 2007-07-03 | 2014-12-23 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. |
| CN101790515A (zh) | 2007-07-27 | 2010-07-28 | 埃科特莱茵药品有限公司 | 反式-3-氮杂-双环[3.1.0]己烷衍生物 |
| KR20100046047A (ko) | 2007-07-27 | 2010-05-04 | 액테리온 파마슈티칼 리미티드 | 2-아자-비시클로[3.3.0]옥탄 유도체 |
| AU2008281876A1 (en) | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | Monoamide derivatives as orexin receptor antagonists |
| US8003797B2 (en) | 2007-08-09 | 2011-08-23 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| AU2008287445A1 (en) | 2007-08-10 | 2009-02-19 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| BRPI0815079A2 (pt) | 2007-08-15 | 2015-02-03 | Actelion Pharmaceuticals Ltd | Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto |
| WO2009040730A2 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| US8362009B2 (en) | 2007-10-29 | 2013-01-29 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| WO2009079637A1 (en) | 2007-12-18 | 2009-06-25 | Concert Pharmaceuticals, Inc. | Tetrahydroisoquinoline derivatives |
| CA2705411A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| KR101178658B1 (ko) | 2008-01-21 | 2012-08-30 | 에프. 호프만-라 로슈 아게 | 오렉신 길항제로서의 설폰아마이드 |
| ES2367341T3 (es) | 2008-02-12 | 2011-11-02 | F. Hoffmann-La Roche Ag | Derivados de piperidina-sulfonamida. |
| EP2247586B1 (en) | 2008-02-21 | 2012-04-25 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| KR20110020906A (ko) | 2008-06-11 | 2011-03-03 | 액테리온 파마슈티칼 리미티드 | 오렉신 수용체 안타고니스트로서의 테트라졸 화합물 |
| KR20110025915A (ko) | 2008-06-16 | 2011-03-14 | 에프. 호프만-라 로슈 아게 | 오렉시닌 수용체 길항제로서 헤테로방향족 모노아마이드 |
| KR20110036069A (ko) | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물 |
| WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| ES2386526T3 (es) | 2008-07-29 | 2012-08-22 | F. Hoffmann-La Roche Ag | Pirrolidin-3-ilmetilaminas, como antagonistas de orexina |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| EP2161266A1 (en) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuran derivatives as orexin receptor antagonists |
| KR20110071004A (ko) | 2008-10-14 | 2011-06-27 | 액테리온 파마슈티칼 리미티드 | 페네틸아미드 유도체 및 이의 헤테로시클릭 유사체 |
| CA2739916A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| WO2010048014A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| EP2350066B1 (en) | 2008-10-21 | 2013-08-28 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| JP2012506379A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 二置換アゼパンオレキシン受容体アンタゴニスト |
| AU2009307916A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| US8357700B2 (en) | 2008-10-21 | 2013-01-22 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| AU2009308981A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| MX2011004551A (es) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| WO2010051238A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2370427A1 (en) | 2008-12-02 | 2011-10-05 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
| US20100144760A1 (en) | 2008-12-02 | 2010-06-10 | Giuseppe Alvaro | Novel compounds |
| JP2010155827A (ja) | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| AR077525A1 (es) | 2009-01-30 | 2011-09-07 | Novartis Ag | 4-aril-butan-1,3-diamidas y composiciones farmaceuticas |
| KR20120007061A (ko) | 2009-04-24 | 2012-01-19 | 글락소 그룹 리미티드 | 오렉신 길항제로서 사용되는 3-아자비시클로［4.1.0］헵탄 |
| EP2451281A4 (en) | 2009-07-09 | 2013-03-13 | Merck Sharp & Dohme | TETRAHYDRONAPHTHYDRIN-orexin receptor Antagonist |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
| US20120149711A1 (en) | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| WO2011023578A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| HUE043962T2 (hu) | 2009-10-23 | 2019-09-30 | Janssen Pharmaceutica Nv | Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011053522A1 (en) | 2009-10-29 | 2011-05-05 | Merck Sharp & Dohme Corp. | Tertiary amide orexin receptor antagonists |
| WO2011061318A1 (en) | 2009-11-23 | 2011-05-26 | N.V. Organon | Heterocylic compounds as antagonists of the orexin receptors |
| WO2011073316A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| WO2011076747A1 (en) | 2009-12-21 | 2011-06-30 | Novartis Ag | Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| US8742106B2 (en) | 2009-12-21 | 2014-06-03 | Novartis Ag | Disubstituted heteroaryl-fused pyridines |
| WO2011138266A1 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indolizine and imidazopyridine derivatives as orexin receptor antagonists |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| US20130281465A1 (en) | 2010-12-17 | 2013-10-24 | Taisho Pharmaceutical Co., Ltd. | Pyrazole derivative |
| US20120165331A1 (en) | 2010-12-22 | 2012-06-28 | Sangamesh Badiger | Di/tri-aza-spiro-C9-C11alkanes |
| WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| EP2484674A1 (en) * | 2011-02-02 | 2012-08-08 | Rottapharm S.P.A. | Spiro aminic compounds with NK1 antagonist activity |
| US9303023B2 (en) | 2011-02-18 | 2016-04-05 | Actelion Pharmaceuticals Ltd. | Pyrazole and imidazole derivatives useful as orexin antagonists |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| WO2012153729A1 (ja) | 2011-05-10 | 2012-11-15 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
| EP2730573A4 (en) | 2011-07-05 | 2014-12-03 | Taisho Pharmaceutical Co Ltd | METHYLPIPERIDINDERIVAT |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US9029364B2 (en) | 2011-10-21 | 2015-05-12 | Merck Sharp & Dohme Corp. | 2,5-disubstituted thiomorpholine orexin receptor antagonists |
| US9242995B2 (en) | 2011-10-25 | 2016-01-26 | Merck Sharp & Dohme Corp. | Isoxazolopyridine orexin receptor antagonists |
| WO2013062857A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Piperidinyl alkyne orexin receptor antagonists |
| TWI565703B (zh) | 2011-11-08 | 2017-01-11 | 艾克泰聯製藥有限公司 | ２-（１，２，３-三唑-２-基）苯甲醯胺及３-（１，２，３-三唑-２-基）吡啶醯胺衍生物 |
| ITMI20112329A1 (it) | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| EP2811997B1 (en) * | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| CA2861493C (en) | 2012-02-17 | 2019-09-24 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| ITMI20120322A1 (it) * | 2012-03-01 | 2013-09-02 | Rottapharm Spa | Composti di 4,4-difluoro piperidina |
| ITMI20120424A1 (it) | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| WO2015123355A1 (en) * | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| AR101558A1 (es) | 2014-08-13 | 2016-12-28 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
| HUE059280T2 (hu) * | 2016-02-12 | 2022-11-28 | Astrazeneca Ab | Halogén-szubsztituált piperidinek mint orexin receptor modulátorok |
-
2017
- 2017-02-10 HU HUE17750847A patent/HUE059280T2/hu unknown
- 2017-02-10 AU AU2017217931A patent/AU2017217931B2/en active Active
- 2017-02-10 RS RS20220714A patent/RS63471B1/sr unknown
- 2017-02-10 MX MX2018009656A patent/MX2018009656A/es unknown
- 2017-02-10 SM SM20220323T patent/SMT202200323T1/it unknown
- 2017-02-10 DK DK17750847.0T patent/DK3414241T3/da active
- 2017-02-10 TW TW106104428A patent/TWI710557B/zh active
- 2017-02-10 EA EA201891714A patent/EA036542B9/ru active IP Right Revival
- 2017-02-10 JP JP2018542231A patent/JP6883045B2/ja active Active
- 2017-02-10 KR KR1020187025645A patent/KR102738491B1/ko active Active
- 2017-02-10 HR HRP20220906TT patent/HRP20220906T1/hr unknown
- 2017-02-10 TN TNP/2018/000280A patent/TN2018000280A1/en unknown
- 2017-02-10 PT PT177508470T patent/PT3414241T/pt unknown
- 2017-02-10 CR CR20180429A patent/CR20180429A/es unknown
- 2017-02-10 SI SI201731191T patent/SI3414241T1/sl unknown
- 2017-02-10 US US16/076,818 patent/US10894789B2/en active Active
- 2017-02-10 BR BR112018016446-1A patent/BR112018016446B1/pt active IP Right Grant
- 2017-02-10 EP EP17750847.0A patent/EP3414241B1/en active Active
- 2017-02-10 WO PCT/US2017/017408 patent/WO2017139603A1/en not_active Ceased
- 2017-02-10 CN CN201780022666.9A patent/CN109219606B/zh active Active
- 2017-02-10 MY MYPI2018702747A patent/MY195239A/en unknown
- 2017-02-10 PL PL17750847.0T patent/PL3414241T3/pl unknown
- 2017-02-10 SG SG11201806368VA patent/SG11201806368VA/en unknown
- 2017-02-10 ES ES17750847T patent/ES2923790T3/es active Active
- 2017-02-10 CA CA3013927A patent/CA3013927C/en active Active
- 2017-02-10 LT LTEPPCT/US2017/017408T patent/LT3414241T/lt unknown
-
2018
- 2018-07-26 IL IL260788A patent/IL260788B/en unknown
- 2018-08-06 DO DO2018000179A patent/DOP2018000179A/es unknown
- 2018-08-07 SV SV2018005731A patent/SV2018005731A/es unknown
- 2018-08-07 CL CL2018002121A patent/CL2018002121A1/es unknown
- 2018-08-10 PH PH12018501708A patent/PH12018501708A1/en unknown
- 2018-08-30 ZA ZA2018/05839A patent/ZA201805839B/en unknown
- 2018-09-04 CO CONC2018/0009290A patent/CO2018009290A2/es unknown
-
2020
- 2020-12-09 US US17/116,773 patent/US11434236B2/en active Active
-
2022
- 2022-07-20 US US17/868,856 patent/US12084437B2/en active Active
- 2022-07-28 CY CY20221100519T patent/CY1125461T1/el unknown
-
2024
- 2024-08-07 US US18/797,152 patent/US20240400550A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201613902A (en) | Difluoropyrrolidines as orexin receptor modulators | |
| PH12018501708A1 (en) | Halo-substituted piperidines as orexin receptor modulators | |
| MX2023004306A (es) | Un antagonista de il-4r para usarse en prevenir o tratar la alergia. | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
| UA112514C2 (uk) | АНТАГОНІСТИ C5aR | |
| MX356599B (es) | Composicion para reducir la sensacion de trpa1 y trpv1. | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| MY175708A (en) | Dna antibody constructs and method of using same | |
| MX2016002571A (es) | Regulador de ph de transduccion. | |
| BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
| AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| EA201270591A1 (ru) | ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ | |
| CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
| DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| EA201592238A1 (ru) | Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма | |
| FI20135146A7 (fi) | Farmaseuttiset koostumukset ja hoitomenetelmät | |
| PH12016501619A1 (en) | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| NZ730334A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| EP3738977C0 (en) | EXTRACELLULAR DOMAIN OF FC IGE RECEPTOR ALPHA SUBUNIT, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PROCESS FOR PRODUCING IT | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| BRPI0907220A2 (pt) | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf | |
| MX2015015194A (es) | Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales. |